These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6087085)

  • 1. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma.
    Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H
    Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glucagonoma syndrome: stimulus-induced plasma responses of circulating glucagon components IRG9000 and IRG3500.
    Hendriks T; Jansen JB; van Tongeren JH
    Acta Endocrinol (Copenh); 1984 Feb; 105(2):226-32. PubMed ID: 6141691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibitory effects of somatostatin analog (SMS 201-995) on pancreatic hormones in patients with malignant islet-cell carcinoma].
    Fukushima H; Ueno S; Sakakida M; Takahashi T; Shirotani T; Araki E; Kishikawa H; Yamaguchi K; Nakamura N; Uzawa H
    Nihon Naibunpi Gakkai Zasshi; 1988 Aug; 64(8):666-76. PubMed ID: 2852126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome.
    Fujita J; Seino Y; Ishida H; Taminato T; Matsukura S; Horio T; Imamura S; Naito A; Tobe T; Takahashi K
    Cancer; 1986 Feb; 57(4):860-5. PubMed ID: 2867823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".
    Recant L; Perrino PV; Bhathena SJ; Danforth DN; Lavine RL
    Diabetologia; 1976 Aug; 12(4):319-26. PubMed ID: 183997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
    Torre L; Vazquez JA; Blázquez E
    Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the liver in glucagon metabolism.
    Jaspan JB; Huen AH; Morley CG; Moossa AR; Rubenstein AH
    J Clin Invest; 1977 Aug; 60(2):421-8. PubMed ID: 874100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excessive circulating large molecular weight immunoreactive glucagon components in subjects with the idiopathic postprandial syndrome.
    Charles MA; Waldeck N
    J Clin Endocrinol Metab; 1981 Aug; 53(2):366-71. PubMed ID: 6265488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential immunoreactivity of plasma glucagon components in man: studies with different glucagon antibodies.
    Soybel D; Jaspan J; Polonsky K; Goldberg I; Rayfield E; Tager H
    J Clin Endocrinol Metab; 1983 Mar; 56(3):612-8. PubMed ID: 6185527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size heterogeneity of immunoreactive glucagon during bile-duct obstruction in the rabbit.
    Sanke T
    Endocrinol Jpn; 1982 Oct; 29(5):541-51. PubMed ID: 6763562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
    Valverde I; Lemon HM; Kessinger A; Unger RH
    J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent pheochromocytoma associated with glucagonoma. A case report.
    Yao H; Fukiyama K; Kawano Y; Mizumoto K; Toyoshima S; Omae T
    Endocrinol Jpn; 1983 Apr; 30(2):163-6. PubMed ID: 6139277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin.
    Danforth DN; Triche T; Doppman JL; Beazley RM; Perrino PV; Recant L
    N Engl J Med; 1976 Jul; 295(5):242-5. PubMed ID: 180408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant glucagonoma syndrome: response to chemotherapy.
    Marynick SP; Fagadau WR; Duncan LA
    Ann Intern Med; 1980 Sep; 93(3):453-4. PubMed ID: 6254416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver.
    Jaspan JB; Polonsky KS; Röjdmark S; Ishida T; Field JB; Rubenstein AH
    Diabetes; 1981 Sep; 30(9):767-72. PubMed ID: 7262472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case with glucagonoma syndrome--heterogeneity of glucagon and insulin.
    Fukushima H; Yamaguchi K; Uzawa H
    Endocrinol Jpn; 1981 Oct; 28(5):575-82. PubMed ID: 6284494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancy of fasting plasma glucagon levels measured by different glucagon antisera.
    Tahara Y; Tanaka A; Yamamoto Y; Fukuda M; Kumahara Y; Shima K
    Diabetes Res; 1988 Apr; 7(4):179-83. PubMed ID: 3402167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.
    Holst JJ
    Diabetologia; 1983 May; 24(5):359-65. PubMed ID: 6307793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement and partial characterization of immunoreactive glucagon in gastrointestinal tissues of dogs.
    Morita S; Doi K; Yip CC; Vranic M
    Diabetes; 1976 Nov; 25(11):1018-25. PubMed ID: 186345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.